Results 161 to 170 of about 1,054,313 (264)

Potential reasons for the decline of new HIV cases among people who inject drugs (PWID) in Kyrgyzstan. [PDF]

PLoS One
Moldokmatova A, Pan-Ngum W, Ariana P, Franco C, Aguas R, Zhumalieva C, Asangozhoeva Z, White L.   +7 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Pre-Exposure Prophylaxis Adherence and HIV Self-Testing App Among Women in the South Bronx: 12-Month Usability, Acceptability, and Feasibility Study. [PDF]

JMIR Form Res
Wright CG, Chern TL, Abularrage TF, Franks J, Kahn A, Edwards S, Chellani HH, Redd R, Ying AW, Arumugam S, Stanciu R, Sia SK, Morrison EA, Justman JE.   +13 more
europepmc   +1 more source

AIDS and HIV [PDF]

Nature, 1988
openaire   +2 more sources

Membrane‐Permeable Nucleoside T‐1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides

Chemistry – A European Journal, EarlyView.
Favipiravir (T‐705) and the non‐fluorinated counterpart (T‐1106) are antiviral agents that inhibit the RNA‐dependent RNA polymerase (RdRp) of various RNA viruses. The antiviral efficacy of nucleoside analogues is strongly dependent on their intracellular activation by cellular kinases to produce their corresponding triphosphate metabolites (T‐705‐RTP ...
Chris Meier, Duan Li, Leentje Persoons, Graciela Andrei, Robert Snoeck, Dominique Schols, Lieve Naesens, Xiao Jia   +7 more
wiley   +1 more source

Alterations to the Bronchial Gene-Expression Effects of Tobacco Smoking in People Living With HIV. [PDF]

J Acquir Immune Defic Syndr
Lee M, Olson A, Pickering RT, Ieong MH, Kivett D, Roche S, Xiao X, Liu G, Asundi A, Lin NH, Lenburg ME.   +10 more
europepmc   +1 more source

Effectiveness of HIV Status Disclosure Interventions Among Children and Adolescents in Low and Middle-Income Countries: A Systematic Review. [PDF]

Pediatric Health Med Ther
Kirabira J, Atim LM, Spencer A.
europepmc   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Exploring HIV prevention preferences among key populations in Uganda: A qualitative study. [PDF]

PLoS One
Block Ngaybe MG, Joseph KK, Hamzazai W, Deal CJ, Mugamba S, Stephen WM, Muhumuza R, Nakaggwa B, Abubakar A, Valdez G, Ingram M, Ehiri J, Mirembe G, Mwesigwa B, Kibuuka H, Madhivanan P.   +15 more
europepmc   +1 more source

Reducing Exposure Before Birth: An Interrupted Time Series Study of Prenatal Exposure to Fetotoxic Medications Under Risk Management Plans in Canada

Clinical Pharmacology &Therapeutics, EarlyView.
Canada's 2009 risk management plan (RMP) framework has not been evaluated for prenatal exposure impact. Conversely, widely used drugs such as nonsteroidal anti‐inflammatory drugs (NSAIDs) lack RMPs. We assessed first‐trimester exposure to RMP‐regulated medications following regulatory interventions and to NSAIDs following safety publications.
Nahiyan Saiyara Khan, Odile Sheehy, Lisiane Freitas Leal, Vanina Tchuente, Anick Bérard   +4 more
wiley   +1 more source